24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
Spotlight
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Fosun Pharma
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
22:32
CyberArk, not SentinelOne, was always the goal, says Palo Alto CEO
21:39
Palo Alto CEO on $25B CyberArk deal: “This is the lowest our stock will be for the next five years”
21:32
CyberArk’s $25B exit enriches global funds, not Israelis
20:15
Check Point not for sale, says CEO as Palo Alto buys CyberArk for $25B
More stories
Buzz
Most popular
Daily
Weekly
1
Palo Alto closing on over $20 billion acquisition of CyberArk
2
Wiz finds major security flaw in Base44, one month after Wix acquisition
3
Palo Alto to acquire CyberArk for $25B in landmark cybersecurity deal
4
Intel’s global overhaul: What the memo didn’t say
5
Intel veterans raise $40 million to scale AI surveillance platform
More news
Fosun Pharma
8 stories about Fosun Pharma
Israel's Mitrassist Medical raises $50 million for medical valve development
02.12.20
|
Meir Orbach
China's Fosun Pharma, insurance company Ping-An and four large Chinese funds all took part in the round
Double-chin reducing Israeli startup closes $74 million China licensing deal
22.09.20
|
Meir Orbach
The agreement provides JuveStar with exclusive rights to develop and commercialize Raziel Therapeutics’ proprietary RZL-012 compound
Fosun Whetted Our Appetite, Says Alma Lasers CEO
04.07.19
|
Golan Hazani
Fosun Pharma CEO Yifang Wu and Alma Lasers CEO Lior Dayan gave Calcalist their first joint interview since the Chinese conglomerate acquired the Israeli medical laser company in 2013
Fosun Pharma Subsidiary Sisram Medical Leases 11,000-Square-Meter Building in Caesarea
10.12.18
|
Dotan Levy
The ten-year lease is estimated at $1.7 million (NIS 6.3 million) per year. China’s Fosun Pharma bought Sisram in 2014 for $240 million, renaming it from Alma Lasers
Fosun Pharma Acquires Israeli Distributer Via Israeli Subsidiary Sisram
28.11.18
|
Golan Hazani
Sisram Medical, formerly Alma Lasers, is buying Nova Medical, one of the largest distributors of medical aesthetic devices in Israel
Fosun Leads $30 Million Round for Heart Valve Company MitrAssist
08.11.17
|
Lilach Baumer
The Israel-based company develops a valve implant that can be installed through thigh catheterization instead of invasive heart surgery
Sisram Stock Price Down on Market Debut
19.09.17
|
Amarelle Wenkert
The Fosun Pharma subsidiary debuted on the Hong Kong Stock Exchange Tuesday
Sisram Medical Seeks to Raise Up To $176 Million in Hong Kong IPO
10.09.17
|
Amarelle Wenkert
On September 5, the Fosun Pharma subsidiary submitted a prospectus to the Hong Kong Stock Exchange